IL247379A0 - A method for treating depression and major depressive disorder - Google Patents

A method for treating depression and major depressive disorder

Info

Publication number
IL247379A0
IL247379A0 IL247379A IL24737916A IL247379A0 IL 247379 A0 IL247379 A0 IL 247379A0 IL 247379 A IL247379 A IL 247379A IL 24737916 A IL24737916 A IL 24737916A IL 247379 A0 IL247379 A0 IL 247379A0
Authority
IL
Israel
Prior art keywords
depressive disorder
major depressive
treating depression
depression
treating
Prior art date
Application number
IL247379A
Other languages
English (en)
Hebrew (he)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of IL247379A0 publication Critical patent/IL247379A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL247379A 2014-03-05 2016-08-21 A method for treating depression and major depressive disorder IL247379A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461948529P 2014-03-05 2014-03-05
US201462061417P 2014-10-08 2014-10-08
PCT/US2015/018701 WO2015134585A1 (en) 2014-03-05 2015-03-04 Method for treating depression and major depressive disorder

Publications (1)

Publication Number Publication Date
IL247379A0 true IL247379A0 (en) 2016-11-30

Family

ID=54055831

Family Applications (1)

Application Number Title Priority Date Filing Date
IL247379A IL247379A0 (en) 2014-03-05 2016-08-21 A method for treating depression and major depressive disorder

Country Status (12)

Country Link
US (1) US20170137880A1 (enExample)
EP (1) EP3114239A4 (enExample)
JP (1) JP2017512204A (enExample)
KR (1) KR20160127126A (enExample)
CN (1) CN106536751A (enExample)
AU (1) AU2015227296A1 (enExample)
CA (1) CA2940683A1 (enExample)
IL (1) IL247379A0 (enExample)
MA (1) MA39485A (enExample)
MX (1) MX2016011384A (enExample)
RU (1) RU2016138574A (enExample)
WO (1) WO2015134585A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
PL3528811T3 (pl) * 2017-03-30 2022-01-10 Rundle Research, LLC Wortioksetyna i inhibitory mao do leczenia depresji
EP3909600A1 (en) * 2020-05-12 2021-11-17 International Centre For Genetic Engineering And Biotechnology - ICGEB Emid2 protein as anti-cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2439201B1 (en) * 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
EP2581454B1 (en) * 2008-01-17 2015-09-16 Suregene LLC Genetic markers of mental illness
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2622101A4 (en) * 2010-10-01 2014-04-02 Rigshospitalet Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors
US9243464B2 (en) * 2011-02-10 2016-01-26 Baker Hughes Incorporated Flow control device and methods for using same
WO2012109565A1 (en) * 2011-02-10 2012-08-16 Neurotherics, Llc Genetic identification of response to antidepressant medications
AU2012340015B2 (en) * 2011-11-14 2017-09-21 Alfasigma S.P.A. Assays for selecting a treatment regimen for a subject with depression and methods for treatment

Also Published As

Publication number Publication date
EP3114239A1 (en) 2017-01-11
KR20160127126A (ko) 2016-11-02
RU2016138574A (ru) 2018-04-06
CN106536751A (zh) 2017-03-22
WO2015134585A1 (en) 2015-09-11
MX2016011384A (es) 2017-05-01
JP2017512204A (ja) 2017-05-18
CA2940683A1 (en) 2015-09-11
US20170137880A1 (en) 2017-05-18
RU2016138574A3 (enExample) 2018-10-12
AU2015227296A1 (en) 2016-09-08
MA39485A (fr) 2015-09-11
EP3114239A4 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
SG10201913085TA (en) Methods and compositions for treating a serpinc1-associated disorder
ZA201705673B (en) Methods for treating skin
IL255463A (en) Methods and kits for treating depression
SG11201703193XA (en) Treatment for depression and depressive disorders
GB201507384D0 (en) Control apparatus and related method
GB201509463D0 (en) Improved apparatus and method
IL248803A0 (en) Means and methods for treating cmv
IL251215A0 (en) Cannabinoid preparation and method for treating pain
GB2524060B (en) Controller and method
IL251759A0 (en) Preparations and methods for treating insomnia
IL254393A0 (en) Methods for treating diseases associated with pathological changes in protein
GB2528343B (en) Method and apparatus for efficiently executing hash operations
GB201501258D0 (en) Controller and method
PL2913284T3 (pl) Sposób oraz urządzenie do obróbki części
PL3220952T3 (pl) Sposób leczenia lub zapobiegania udarowi
IL252904A0 (en) Methods and factors for treating diseases
GB201421385D0 (en) Composition and method for treating nematodes
IL273155A (en) Methods for treating depression and major depressive disorders
IL247379A0 (en) A method for treating depression and major depressive disorder
IL255012A0 (en) Preparations and methods for treating skin conditions
PL3323113T3 (pl) Urządzenie i sposób uwierzytelniania
PL3134581T3 (pl) Sposób i środek do stabilizacji gruntu
HK1230248A1 (en) Method for treating depression and major depressive disorder
SG10201405253QA (en) Apparatus and Method for Treating
GB201513195D0 (en) Improved radiotherapeutic apparatus and method